These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 2425959

  • 1. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM.
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
    Heideman RL, Gillespie A, Ford H, Reaman GH, Balis FM, Tan C, Sato J, Ettinger LJ, Packer RJ, Poplack DG.
    Cancer Res; 1989 Sep 15; 49(18):5213-6. PubMed ID: 2475244
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J.
    Cancer Res; 1987 Jan 15; 47(2):617-23. PubMed ID: 3791246
    [Abstract] [Full Text] [Related]

  • 5. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP.
    Clin Cancer Res; 2001 Jan 15; 7(1):43-50. PubMed ID: 11205916
    [Abstract] [Full Text] [Related]

  • 6. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.
    Clin Cancer Res; 2000 Apr 15; 6(4):1259-66. PubMed ID: 10778949
    [Abstract] [Full Text] [Related]

  • 7. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Apr 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 9. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
    Curt GA, Kelley JA, Fine RL, Huguenin PN, Roth JS, Batist G, Jenkins J, Collins JM.
    Cancer Res; 1985 Jul 15; 45(7):3359-63. PubMed ID: 2408749
    [Abstract] [Full Text] [Related]

  • 10. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 11. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 15; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
    Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G.
    Cancer Res; 1991 Feb 15; 51(4):1105-8. PubMed ID: 1705165
    [Abstract] [Full Text] [Related]

  • 13. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A, Ford H, Kelley JA, Ben-Baruch N, Thomas RV, Fine R, Cowan KH.
    Cancer Res; 1990 Feb 15; 50(4):1220-5. PubMed ID: 1688736
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
    Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2363-70. PubMed ID: 9815635
    [Abstract] [Full Text] [Related]

  • 16. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, McCarthy S, Bailey NP, Siddiqui N, Lind MJ, Calvert AH, Twelves CJ, Cassidy J, Kaye SB.
    Clin Cancer Res; 1998 Mar 01; 4(3):605-10. PubMed ID: 9533527
    [Abstract] [Full Text] [Related]

  • 17. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 18. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A.
    Cancer Treat Rep; 1985 Apr 01; 69(4):409-16. PubMed ID: 3995511
    [Abstract] [Full Text] [Related]

  • 19. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 2003 Nov 15; 9(15):5540-9. PubMed ID: 14654534
    [Abstract] [Full Text] [Related]

  • 20. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB.
    Cancer Res; 1990 Jun 01; 50(11):3284-8. PubMed ID: 2334921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.